Get the Stockscreener App
8.015
0.69%
0.055
After Hours:
8.10
0.085
+1.06%
10 X Genomics Inc stock is traded at $8.015, with a volume of 4.43M.
It is up +0.69% in the last 24 hours and down -22.86% over the past month.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
See More
Previous Close:
$7.96
Open:
$8.42
24h Volume:
4.43M
Relative Volume:
1.41
Market Cap:
$988.76M
Revenue:
$631.73M
Net Income/Loss:
$-239.78M
P/E Ratio:
-3.9678
EPS:
-2.02
Net Cash Flow:
$-33.45M
1W Performance:
-0.19%
1M Performance:
-22.86%
6M Performance:
-46.92%
1Y Performance:
-70.94%
1-Day Range:
$7.94
$8.67
1-Week Range:
$7.25
$8.67
52-Week Range:
$6.78
$29.37
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
8.015 | 988.76M | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
220.53 | 35.90B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
54.22 | 9.90B | 516.85M | 174.11M | 217.38M | 0.87 |
|
HQY
Healthequity Inc
|
86.08 | 7.46B | 1.15B | 96.70M | -161.99M | 1.09 |
|
TEM
Tempus Ai Inc
|
49.55 | 7.07B | 640.44M | -743.28M | -206.93M | -11.29 |
|
WAY
Waystar Holding Corp
|
36.80 | 6.32B | 906.14M | -52.62M | 89.62M | -0.3621 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-22-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-10-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Hold |
| May-01-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
Advancing the Future of Biomarker-Driven Immunotherapy - Fierce Biotech
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis (PR Newswire) - Aktiellt
10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025 - BioSpace
BofA Securities Cuts Price Target on 10x Genomics to $12 From $16, Neutral Rating Maintained - marketscreener.com
10x Genomics (TXG) Price Target Reduced Amid Policy and Economic Concerns | TXG Stock News - GuruFocus
Biotech Leader 10x Genomics Announces Q1 2025 Earnings Date: What to Watch - Stock Titan
Positive Sentiment Still Eludes 10x Genomics, Inc. (NASDAQ:TXG) Following 29% Share Price Slump - simplywall.st
Spatial Genomics Transcriptomics Market Is Booming Worldwide | - openPR.com
Single-cell Omics Emerging Technologies and Markets Report - GlobeNewswire
Single-cell Omics Emerging Technologies and Markets Report 2025: 10x Genomics, Thermo Fisher & Illumina Lead $9.1 Billion Single-cell Omics Market by 2029 - Yahoo Finance
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know - Yahoo Finance
10x Genomics Reports Third Quarter 2023 Financial Results - Seeking Alpha
10X Genomics stock hits 52-week low at $7.43 amid market challenges - Investing.com Canada
10X Genomics stock hits 52-week low at $7.43 amid market challenges By Investing.com - Investing.com South Africa
10 Promising Biotech Stocks to Invest in (April 2025) - Securities.io
IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10X Genomics stock plunges to 52-week low of $9.27 By Investing.com - Investing.com South Africa
10X Genomics stock plunges to 52-week low of $9.27 - Investing.com
We Think 10x Genomics (NASDAQ:TXG) Can Easily Afford To Drive Business Growth - Yahoo Finance
UPC infringement case can resume after EPO upholds 10x Genomics patent - JUVE Patent
10x Genomics Comments on Second UPC Preliminary Injunction Decis - GuruFocus.com
10x Genomics: Lower Cost Innovation May Drive A Rebound - Seeking Alpha
These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company
Long Read Sequencing Market Top Companies Study10X Genomics, - openPR
2 Reasons to Sell TXG and 1 Stock to Buy Instead - Yahoo Finance
Bruker motion backfires in US patent dispute with 10x Genomics, Harvard - MLex
Press Release Distribution & PR Platform - ACCESS Newswire
10x Genomics IncOrdinary SharesClass A to Host Earnings Call - ACCESS Newswire
10x Genomics’ (TXG) Sell (E+) Rating Reiterated at Weiss Ratings - Defense World
Citigroup Issues Pessimistic Forecast for 10x Genomics (NASDAQ:TXG) Stock Price - Defense World
Strategic Move: Healthcare Giant Zimmer Biomet Taps Communications Veteran from 10x Genomics - Stock Titan
10x Genomics gets injunction against Parse Biosciences' ATAC Products - MSN
10x Genomics Dodges Appeal In DNA Analysis Patent Clash - Law 360 UK
10x genomics CEO Serge Saxonov sells $84,393 in stock By Investing.com - Investing.com Australia
Rhumbline Advisers Sells 1,641 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
10x genomics CEO Serge Saxonov sells $84,393 in stock - Investing.com
Sanctuary Advisors LLC Purchases 6,474 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
Short Interest in 10x Genomics, Inc. (NASDAQ:TXG) Expands By 34.4% - Defense World
10x Genomics Secures Injunction Against Parse Biosciences' Plann - GuruFocus.com
10x Genomics Secures Injunction Against Parse Biosciences’ Planned ATAC Products - The Malaysian Reserve
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products - Marketscreener.com
10x Genomics secures injunction against Parse Biosciences - Investing.com
10x Genomics gets injunction against Parse Biosciences' ATAC Products (TXG:NASDAQ) - Seeking Alpha
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products – Company Announcement - Financial Times
ARK Investment Management LLC Purchases 1,193,712 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
SVB Wealth LLC Acquires Shares of 522,609 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
Ieq Capital LLC Purchases 50,722 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
ING Groep NV Acquires New Shares in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics, Inc. (NASDAQ:TXG) CEO Sells $56,368.44 in Stock - MarketBeat
Director of 10x Genomics Picks Up 184% More Stock - Simply Wall St
Oxford Nanopore Expands Compatibility With 10x Genomics To Unlock Deeper Insights in Single-Cell Transcriptomics - Technology Networks
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.12%
2.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):